Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.
Saved in:
| Title: | Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study. |
|---|---|
| Authors: | Tassone, Pierfrancesco1,2 (AUTHOR) tassone@unicz.it, Di Martino, Maria Teresa1,2,3 (AUTHOR), Arbitrio, Mariamena2,4 (AUTHOR), Fiorillo, Lucia2,3 (AUTHOR), Staropoli, Nicoletta2,3 (AUTHOR), Ciliberto, Domenico2,3 (AUTHOR), Cordua, Alessia1 (AUTHOR), Scionti, Francesca1 (AUTHOR), Bertucci, Bernardo5 (AUTHOR), Salvino, Angela2,3 (AUTHOR), Lopreiato, Mariangela1 (AUTHOR), Thunarf, Fredrik6 (AUTHOR), Cuomo, Onofrio1 (AUTHOR), Zito, Maria Cristina7 (AUTHOR), De Fina, Maria Rosanna7 (AUTHOR), Brescia, Amelia7 (AUTHOR), Gualtieri, Simona2,3 (AUTHOR), Riillo, Caterina1 (AUTHOR), Manti, Francesco5 (AUTHOR), Caracciolo, Daniele1 (AUTHOR) |
| Source: | Journal of Hematology & Oncology. 6/26/2023, Vol. 16 Issue 1, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17568722 |
|---|---|
| DOI: | 10.1186/s13045-023-01468-8 |
